Study identifier:D4200C00058
ClinicalTrials.gov identifier:NCT00410761
EudraCT identifier:N/A
CTIS identifier:N/A
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Thyroid Cancer
Phase 3
No
ZD6474 (Vandetanib)
All
437
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Apr 2016 by AstraZeneca
AstraZeneca
-
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
Location
Location
Wien, Austria
Location
St Leonards, Australia
Location
Brussels, Belgium
Location
Leuven, Belgium
Location
Porto Alegre, Brazil
Location
Ribeirão Preto, Brazil
Location
Moncton, NB, Canada
Location
London, ON, Canada
Arms | Assigned Interventions |
---|---|
No Intervention: 1 Placebo vandetanib | - |
Experimental: 2 Vandetanib | Drug: ZD6474 (Vandetanib) once daily oral tablet Other Name: ZACTIMA™ |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.